Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co (NYSE:LLY).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don’t know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga‘s options scanner spotted 120 uncommon options trades for Eli Lilly and Co.
This isn’t normal.
The overall sentiment of these big-money traders is split between 35% bullish and 45%, bearish.
Out of all of the special options we uncovered, 39 are puts, for a total amount of $1,794,386, and 81 are calls, for a total amount of $4,052,883.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $610.0 to $1660.0 for Eli Lilly and Co over the recent three months.
Insights into Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Eli Lilly and Co options trades today is 387.99 with a total volume of 2,219.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly and Co’s big money trades within a strike price range of $610.0 to $1660.0 over the last 30 days.
Eli Lilly and Co 30-Day Option Volume & Interest Snapshot
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | PUT | SWEEP | BEARISH | 01/30/26 | $46.45 | $45.4 | $46.45 | $1100.00 | $181.1K | 26 | 47 |
| LLY | CALL | TRADE | BULLISH | 01/16/26 | $269.0 | $269.0 | $269.0 | $800.00 | $134.5K | 2.6K | 11 |
| LLY | PUT | TRADE | BULLISH | 02/20/26 | $24.1 | $23.6 | $23.6 | $1000.00 | $118.0K | 631 | 67 |
| LLY | CALL | TRADE | BULLISH | 07/17/26 | $95.85 | $93.8 | $95.85 | $1120.00 | $95.8K | 24 | 20 |
| LLY | CALL | TRADE | BULLISH | 01/16/26 | $305.0 | $301.95 | $305.0 | $760.00 | $91.5K | 241 | 5 |
About Eli Lilly and Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly’s key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly and Co, it’s now appropriate to focus on the company itself. We aim to explore its current performance.
Eli Lilly and Co’s Current Market Status
- With a volume of 1,133,591, the price of LLY is down -0.73% at $1069.3.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 21 days.
What The Experts Say On Eli Lilly and Co
1 market experts have recently issued ratings for this stock, with a consensus target price of $1250.0.
- An analyst from UBS downgraded its action to Buy with a price target of $1250.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements.
